论文部分内容阅读
目的观察低分子肝素联合黄芪治疗围生期心肌病的临床疗效。方法选择平顶山市第四人民医院2001年6月~2006年12月住院105例围生期心肌病患者,随机分为两组。对照组50例,给常规治疗;治疗组55例,给低分子肝素注射液5000U、12h一次、皮下注射,黄芪注射液30ml,加5%GS250ml内静脉点滴,每日一次,连用7天。结果治疗1周后治疗组与对照组的有效率分别为98%与82%,差异有显著性(P﹥0.05)。3个月后随访治疗组发生栓塞率明现低于对照组。结论低分子肝素联合黄芪治疗围生期心肌病效果好,并发栓塞率低,不良反应少,可作为治疗围生期心肌病的常规用药。
Objective To observe the clinical effect of low molecular weight heparin combined with astragalus on perinatal cardiomyopathy. Methods Pingdingshan Fourth People’s Hospital in June 2001 ~ December 2006 105 cases of perinatal cardiomyopathy patients were randomly divided into two groups. The control group of 50 patients were given routine treatment; the treatment group of 55 patients, given low molecular weight heparin injection 5000U, 12h once, subcutaneous injection, astragalus injection 30ml, plus 5% GS250ml intravenous drip once daily for 7 days. Results After 1 week of treatment, the effective rates of the treatment group and the control group were 98% and 82%, respectively, with significant differences (P> 0.05). Follow-up after 3 months treatment group embolization rate is lower than the control group. Conclusion Low molecular weight heparin combined with astragalus perinatal cardiomyopathy is effective, with low embolization rate and few adverse reactions, which can be used as a routine medication for perinatal cardiomyopathy.